NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Tuesday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ:NURO opened at $3.72 on Tuesday. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The business’s 50-day moving average price is $4.03 and its two-hundred day moving average price is $3.86.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. The firm had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter last year, the company earned ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.